148766-15-8

Basic information

• Product Name: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-
• CAS NO: 148766-15-8
• Molecular Formula: C13H13NO3
• Molecular Weight: 231.251
• Mol File: 148766-15-8.mol
• Article Data: 23

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-(148766-15-8)
• EPA Substance Registry System: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-(148766-15-8)

Safety Data

• Hazardous Substances Data: 148766-15-8(Hazardous Substances Data)

Upstream product

• 625-35-4 trans-chrotonyl chloride 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 99395-88-7 (S)-4-phenyl-2-oxazolidinone 
• 623-68-7 trans-crotonic anhydride 
• 591-97-9 1-chloro-2-butene 
• 623-68-7 crotonic anhydride 
• 107-93-7 (E)-but-2-enoic acid 
• 20989-17-7 (2S)-2-phenylglycinol 
• 2935-35-5 (S)-2-phenylglycine 

Downstream Products

• 112530-04-8 (4S)-3-((4'R,5'R)-1',5'-dimethylcyclohexene-4'-carbonyl)-4-phenyl-2-oxazolidinone 
• 112530-03-7 (4S)-3-((4'S,5'S)-1',5'-dimethylcyclohexene-4'-carbonyl)-4-phenyl-2-oxazolidinone 
• 99395-88-7 (S)-4-phenyl-2-oxazolidinone 
• 132435-54-2 (2S,3S)-3-methylpyroglutamic acid 
• 261768-47-2 o-[N-(α-picolyl)amino]acetophenone 
• 217961-50-7 (S)-3-(S)-3-methyl-6-(trimethylsilyl)hex-5-ynoyl-4-phenyloxazolidin-2-one 
• 917375-46-3 (R)-3-((S)-3-methyl-5-trimethylsilanyl-pent-4-ynoyl)-4-phenyl-oxazolidin-2-one 
• 1432054-82-4 (4S)-3-{(2S)-2-[(S)-[3,5-bis(trifluoromethyl)phenyl](hydroxy)methyl]but-3-enoyl}-4-phenyl-1,3-oxazolidin-2-one 

Relevant articles and documents

Antineoplastic agents. 599. Total synthesis of dolastatin 16

The first 23-step total synthesis of the cyclodepsipeptide dolastatin 16 (1) has been achieved. Synthesis of the dolaphenvaline and dolamethylleuine amino acid units using simplified methods improved the overall efficiency. The formation of the 25-membere

SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN

The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

Nucleophilic halo-michael addition under lewis-base activation

A simple and general conjugate nucleophilic halogenation is presented. The THTO/halosilane combination has shown the ability to act as a nucleophilic halide source in the conjugate addition to a variety of Michael acceptors. In addition, a straightforward diastereoselective halogen installation using α,β-unsaturated acyloxazolidinones as platforms has been developed.